MedicalResearch.com Interview with:
[caption id="attachment_54456" align="alignleft" width="133"]
Dr. Vlahovic[/caption]
Tracey Vlahovic DPM, FFPM, FCPS
Clinical Professor, Department of Podiatric Medicine
Stanley and Pearl Landau Faculty Fellow
Adjunct Professor, Department of Microbiology, Temple
University School of Medicine
On Behalf of Ortho Dermatologics
MedicalResearch.com: What is the background for this study?
Response: JUBLIA® was first approved in 2014 for people 18 years of age and older. However, more and more children are being diagnosed with onychomycosis, so the goal of the study was to determine the safety and efficacy of Jublia in this patient population.
